Preview

Российский кардиологический журнал

Расширенный поиск

Патогенетические и клинические аспекты фибрилляции предсердий при инфаркте миокарда

https://doi.org/10.15829/1560-4071-2021-4307

Полный текст:

Аннотация

В новых клинических рекомендациях отсутствует какая-либо информация о важности активного выявления фибрилляции предсердий (ФП) при инфаркте миокарда (ИМ), а также об особенностях ведения таких пациентов. Целью настоящего обзора явилось представить современные данные о возможных факторах риска, особенностях патогенеза, а также прогностической значимости ФП при ИМ. Анализ литературы показал, что многими исследователями выделяется ФП, которая имелась в анамнезе до ИМ (хроническая ФП) и ФП, которая возникла впервые как осложнение текущего ИМ (“новая” ФП). Последняя, встречаясь довольно часто (от 3% до 28% среди всех пациентов с ИМ), существенно отягощает прогноз для жизни, а также является важным предиктором развития кардиоэмболических осложнений. При этом у каждого третьего пациента с ИМ ФП носит бессимптомный характер, что делает крайне актуальной разработку специальных алгоритмов, направленных на активный поиск данного нарушения ритма.

Об авторах

М. В. Зыков
ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ГБУЗ Городская больница № 4 города Сочи Минздрава Краснодарского края
Россия

Михаил Валерьевич Зыков — доктор медицинских наук, ведущий научный сотрудник лаборатории нейрососудистой патологии отдела клинической кардиологии, врач-кардиолог высшей категории кардиологического отделения № 1



О. Л. Барбараш
ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ФГБОУ ВО Кемеровский государственный медицинский университет Минздрава России
Россия

Ольга Леонидовна Барбараш — доктор медицинских наук, профессор, член-корр. РАН, директор, зав. кафедрой кардиологии и сердечно-сосудистой хирургии



Список литературы

1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019;139:e56e528. doi:10.1161/CIR.0000000000000659.

2. Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol. 2015;66:148-54. doi:10.1016/j.jjcc.2014.11.001.

3. Shiyovich A, Axelrod M, Gilutz H. Early Versus Late New-Onset Atrial Fibrillation in Acute Myocardial Infarction: Differences in Clinical Characteristics and Predictors. Plakht. Angiology. 2019;70(10):921-8. doi:10.1177/0003319719867542.

4. Axelrod M, Gilutz H, Plakht Y, et al. Early atrial fibrillation during acute myocardial infarction may not be an indication for long-term anticoagulation. Angiology. 2020;71(6):559-66. doi:10.1177/0003319720908760.

5. Thomsen PB, Jons C, Raatikainen MP, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122(13):1258-64. doi:10.1161/CIRCULATIONAHA.109.902148.

6. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Effect of type of atrial fibrillation on prognosis in acute myocardial infarction treated invasively. Am J Cardiol. 2012;109(12):1689-93. doi:10.1016/j.amjcard.2012.02.009.

7. Зыков М. В., Кашталап В. В., Быкова И. С. и др. Коморбидность при инфаркте миокарда, осложненном острой сердечной недостаточностью. Российский кардиологический журнал. 2020;25(7):3427. doi:10.15829/15604071-2020-3427.

8. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2020;42(5):373-498. doi:10.1093/eurheartj/ehaa612.

9. Lee JH, Kim S-H, Lee W, et al. New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke. BMJ Open. 2020;10:e039600. doi:10.1136/bmjopen-2020-039600.

10. Braga CG, Ramos V, Martins J, et al. Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Rev Port Cardiol. 2015;34(6):40310. doi:10.1016/j.repc.2015.01.010.

11. Guenancia C, Toucas C, Fauchier L, et al. High rate of recurrence at long-term followup after new-onset atrial fibrillation during acute myocardial infarction. Europace. 2018;20(12):e179-e188. doi:10.1093/europace/euy168.

12. Stamboul K, Zeller M, Fauchier L, Gudjoncik A. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. International Journal of Cardiology. 2014;174(3):611-7. doi:10.1016/j.ijcard.2014.04.158.

13. Sinno H, Derakhchan K, Libersan D, et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107(14):1930-6. doi:10.1161/01.CIR.0000058743.15215.03.

14. Thomas RA, Rubio R, Berne RM. Comparison of the adenine nucleotide metabolism of dog atrial and ventricular myocardium. Journal of Molecular and Cellular Cardiology. 1975;7(2):115-23. doi:10.1016/0022-2828(75)90013-9.

15. Li N, Csepe TA, Hansen BJ, et al. Adenosine-Induced Atrial Fibrillation Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart. Circulation. 2016;134(6):486-98. doi:10.1161/CIRCULATIONAHA.115.021165.

16. Wang J, Yang YM, Zhu J. Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. Herz. 2015;40(1):18-26. doi:10.1007/s00059-014-4149-3.

17. Opincariu D, Chițu IM. Atrial fibrillation and acute myocardial infarction — an inflammation-mediated association. Journal of Cardiovascular Emergencies. 2018;4(3):123-32. doi:10.2478/jce-2018-0020.

18. Harada M, Van Wagoner DR. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79:495-502. doi:10.1253/circj.CJ-15-0138.

19. Korantzopoulos P, Letsas KP, Tse G, et al. Inflammation and atrial fibrillation: A comprehensive review. 2018;34(4):394-401. doi:10.1002/joa3.12077.

20. Bas HA, Aksoy F, Icli A, et al. The association of plasma oxidative status and inflammation with the development of atrial fibrillation in patients presenting with ST elevation myocardial infarction. Scan J of Clin Lab Invest. 2017;77(2):77-82. doi:10.1080/003655 13.2016.1244857.

21. Cirakoglu OF, Aslan AO, Akyuz AR, et al. The value of syntax score to predict new‐ onset atrial fibrillation in patients with acute coronary syndrome. Ann Noninvasive Electrocardiol. 2019;24(4):e12622. doi:10.1111/anec.12622.

22. Borissoff JI, Joosen IA, Versteylen MO, et al. Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JACC Cardiovasc Imaging. 2012;5:1201-10. doi:10.1016/j.jcmg.2012.01.023.

23. Smid M, Dielis AWJH, Winkens M, et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost. 2011;9:450-6. doi:10.1111/j.15387836.2010.04162.x.

24. Koren O, Azaizah M, Rozner E, et al. Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. Journal of Thrombosis and Thrombolysis. 2019;50(3):144-50. doi:10.1007/s11239-019-01996-6.

25. Jumeau C, Rupin A, Chieng-Yane P, et al. Direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats. JACC: basic to translational science. 2016;1(5):328-39. doi:10.1016/j.jacbts.2016.05.002.

26. Chang CJ, Chen YC, Kao YH, et al. Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. Circ Arrhythm Electrophysiol. 2012;5:1176-83. doi:10.1161/CIRCEP.112.971556.

27. Spronk HMH, De Jong AM, Verheule S, et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J. 2017;38(1):38-50. doi:10.1093/eurheartj/ehw119.

28. Kundu A, O’Daya K, Shaikh AY, et al. Relation of atrial fibrillation in acute myocardial infarction to in hospital complications and early hospital readmission. Am J Cardiol. 2016;117(8):1213-8. doi:10.1016/j.amjcard.2016.01.012.

29. Congo KH, Belo A, Carvalho J, et al. New-onset atrial fibrillation in st-segment elevation myocardial infarction: predictors and impact on therapy and mortality. Arq Bras Cardiol. 2019;113(5):948-57. doi:10.5935/abc.20190190.

30. Lopes RD, Pieper KS, Horton JR, et al. Short and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94:867-73.

31. Ribeiro V, Pereira M, Melão F, et al. Determinants and outcomes of atrial fibrillation complicating myocardial infarction: the EURHOBOP study in Portugal. International Journal of Cardiology. 2014;176(3):1426-8. doi:10.1016/j.ijcard.2014.08.042.

32. Dai Y, Yang J, Gao Z, et al. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry. BMC Cardiovascular Disorders. 2017;17(2):1-8. doi:10.1186/s12872-016-0442-9.

33. Tisminetzky M, Gurwitz JH, Miozzo R, et al. Impact of cardiacand noncardiac-related conditions on adverse outcomes in patients hospitalized with acute myocardial infarction. Journal of Comorbidity. 2019;9:1-9. doi:10.1177/2235042X19852499.

34. Botto F, Alonso-Coello P, Chan MTV, et al. Myocardial injury after noncardiac surgery a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014;120:564-78. doi:10.1097/ALN.0000000000000113.

35. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;39:1038-45. doi:10.1093/eurheartj/ehn579.

36. Kea B, Alligood T, Manning V, Raitt M. A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Current emergency and hospital medicine reports. 2016;4:107-18. doi:10.1007/s40138-016-0105-2.

37. Cosentino N, Ballarotto M, Campodonico J, et al. Impact of glomerular filtration rate on the incidence and prognosis of new-onset atrial fibrillation in acute myocardial infarction. J Clin Med. 2020;9(5):1396. doi:10.3390/jcm9051396.

38. Arslan A, Ozaydin M, Aksoy F, et al. Association between the use of renin-angiotensin system blockers and development of in-hospital atrial fibrillation in patients with ST-segment elevation myocardial infarction. Medicina (Kaunas). 2016;52(2):104-9. doi:10.1016/j.medici.2016.02.006.

39. Aksoy F, Aydin Baş H, Bağcı A, Oskay T. The CHA2DS2-VASc score for predicting atrial fibrillation in patients presenting with ST elevation myocardial infarction: prospective observational study. Sao Paulo Medical Journal. 2019;137(3):248-54. doi:10.1590/15163180.2018.0431140319.

40. van Diepen S, Siha H, Fu Y, et al. APEX AMI Investigators. Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. J Electrocardiol. 2010;43:351-8. doi:10.1016/j.jelectrocard.2010.04.001.

41. Al Khadair D, Alshengieti L, Yan RT, et al. Global Registry of Acute Coronary Events (GRACE/GRACE2) and the Canadian Registry of Coronary Events (CANRACE) Investigators. Can J Cardiol. 2012;28:443-9. doi:10.1016/j.cjca.2011.12.011.

42. Rashid H. Correlation between p wave dispersion and myocardial function in patients with acute myocardial infarction. 2012. https://www.academia.edu/10341841/CORRELATION_BETWEEN_P_WAVE_DISPERSION_AND_MYOCARDIAL_FUNCTION_IN_PATIENTS_WITH_ACUTE_MYOCARDIAL_INFARCTION (15 Jan 2021).

43. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and metaanalysis. Circulation. 2011;123:1587-93. doi:10.1161/CIRCULATIONAHA.110.986661.

44. Angeli F, Reboldi G, Garofoli M, et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep. 2012;14(5):601-10. doi:10.1007/s11886-012-0289-3.

45. Maagh P, Butz T, Wickenbrock I, et al. New-onset versus chronic atrial fibrillation in acute myocardial infarction: differences in shortand long-term follow-up. Clin Res Cardiol. 2011;100(2):167-75. doi:10.1007/s00392-010-0227-6.

46. Zusman O, Amit G, Gilutz H, Zahger D. The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol. 2012;101(1):17-22. doi:10.1007/s00392-011-0357-5.

47. Luo J, Li H, Qin X, et al. Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: A systematic review and meta-analysis. International Journal of Cardiology. 2018;265:125-31. doi:10.1016/j.ijcard.2018.04.096.

48. Bang CN, Gislason GH, Greve AM, et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. J. Am. Heart Assoc. 2014;3(1):e000382. doi:10.1161/JAHA.113.000382.

49. Guimaraes JA, Goncalves FM, Borges S, et al. New onset atrial fibrillation in acute coronary syndrome: early vs late onset. European Heart Journal. 2019:ehz745.0129. doi:10.1093/eurheartj/ehz745.0129.

50. Бхаттарай Р., Сайганов С. А., Трофимова Е. В. Фибрилляция предсердий при инфаркте миокарда различной локализации. Рациональная Фармакотерапия в Кардиологии. 2015;11(1):25-30. doi:10.20996/1819-6446-2015-11-1-25-30.

51. Biasco L, Radovanovic D, Moccetti M, et al. New-onset or pre-existing atrial fibrillation in acute coronary syndromes: two distinct phenomena with a similar prognosis. Rev Esp Cardiol. 2019;72:367-810. doi:1016/j.rec.2018.11.003.

52. Asanin MR, Vasiljevic ZM, Matic MD, et al. The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation. Clin Cardiol. 2009;32(8):467-70. doi:10.1002/clc.20603.

53. Siu CW, Jim MH, Ho HH, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest. 2007;132(1):44-9. doi:10.1378/chest.06-2733.

54. Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: The ECHOES study. Europace. 2012;14:1553-9. doi:10.1093/europace/eus087.

55. Jons C, Jacobsen UG, Joergensen RM, et al. Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction (CARISMA) Study Group. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm. 2011;8(3):342-8. doi:10.1016/j.hrthm.2010.09.090.

56. Lau KK, Chan PH, Yiu KH, et al. Roles of the CHADS2 and CHA2DS2-VASc scores in postmyocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke. Cardiology Journal. 2014;21(5):474-83. doi:10.5603/CJ.a2014.0034.

57. Yin L, Ling X, Zhang Y, et al. CHADS2 and CHA2DS2-VASc scoring systems for predicting atrial fibrillation following cardiac valve surgery. PloS One. 2015;10(4):e0123858. doi:10.1371/journal.pone.0123858.

58. Perrier S, Meyer N, Minh TH, et al. Predictors of atrial fibrillation after coronary artery bypass grafting: a bayesian analysis. Ann Thorac Surg. 2017;103:92-7. doi:10.1016/j.athoracsur.2016.05.115.

59. Saliba W, Gronich N, Barnett-Griness O, et al. Usefulness of CHADS2 and CHA2DS2VASc scores in the prediction of new-onset atrial fibrillation: a population-based study. The American Journal of Medicine. 2016;129(8):843-9. doi:10.1016/j.amjmed.2016.02.029.

60. Абугов С. А., Алекян Б. Г., Архипов М. В. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi:10.15829/29/1560-4071-2020-4103.


Для цитирования:


Зыков М.В., Барбараш О.Л. Патогенетические и клинические аспекты фибрилляции предсердий при инфаркте миокарда. Российский кардиологический журнал. 2021;26(2):4307. https://doi.org/10.15829/1560-4071-2021-4307

For citation:


Zykov M.V., Barbarash O.L. Pathogenesis and clinical significance of atrial fibrillation in myocardial infarction. Russian Journal of Cardiology. 2021;26(2):4307. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4307

Просмотров: 52


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)